



PRESS RELEASE

MINISTRY OF SCIENCE, TECHNOLOGY AND INNOVATION

MEMORANDUM OF AGREEMENT BETWEEN THE NATIONAL INSTITUTES OF BIOTECHNOLOGY MALAYSIA AND CANSINO BIOLOGICS INC., PEOPLE'S REPUBLIC OF CHINA

SELANGOR, 25 July 2024 - A cooperation agreement (MoA) has been signed between the National Institutes of Biotechnology Malaysia (NIBM), an agency under the Ministry of Science, Technology, and Innovation (MOSTI), and CanSino Biologics Inc. from the People's Republic of China.

Prof. Datuk Wira Dr. Raha Abdul Rahim, Chief Executive Officer of NIBM, on behalf of NIBM, signed this memorandum of agreement with Mr. Wang Hong Yi, representing CanSino Biologics Inc., People's Republic of China. This signing is witnessed by YB Tuan Chang Lih Kang, Minister of Science, Technology, and Innovation (MOSTI), along with Mr. Chen Youliang, Minister Counsellor of the Embassy of the People's Republic of China to Malaysia.

"This memorandum of agreement is expected to strengthen the existing relationship between the two countries, particularly between NIBM and CanSino Biologics Inc., through more strategic collaboration focusing on joint research for the developing human vaccine platforms, researcher exchange, technology transfer, and biomanufacturing up to the laboratory testing stage," said YB Chang Lih Kang, Minister of Science, Technology and Innovation.

He added that this aligns with the country's aspiration through the National Vaccine Development Roadmap (NVDR) to produce Malaysia's human vaccines by 2030. This effort is being driven by the Malaysia Genome and Vaccine Institute (MGVI) which is the implementing agency under NIBM, the Malaysian Vaccine Project Office (MVPO), and relevant stakeholders and higher education institutions to ensure the success of the NVDR in driving Malaysia's development of a human vaccine manufacturing ecosystem.

CanSino Biologics Inc. is a global biopharma company established in 2009 with experience producing human vaccines for COVID-19, Meningococcal, and Ebola. The expertise of CanSino Biologics Inc. is precious for Malaysia to benefit from through joint research with MGVI-NIBM in developing vaccine candidates using the mRNA platform. This research and development collaboration includes talent and expert sharing as well as technology transfer and is expected to be completed within two years. This MoA is hoped to strengthen the ecosystem of human vaccine development and research in line with the national aspiration to produce local vaccines by 2030.

#END#

Issued by:

MINISTRY OF SCIENCE, TECHNOLOGY AND INNOVATION
25 July 2024